Fluvoxamine and Ivermectin: Early treatment for COVID-19 is key to better outcomes (2023)
Although the vaccine rollout is greatly reducing the number of people who get seriously ill and are hospitalized with COVID-19, no vaccine offers 100% protection, and new mutations and variants of the virus such as Delta and Omicron are appearing all the time. So it's still important to find new treatments for the illness. In this article, we will cover 2 popular treatments i.e. Fluvoxamine and Ivermectin. Fluvoxamine One of them, the generic drug fluvoxamine, has shown huge potential. Developed 40 years ago as an antidepressant, fluvoxamine—sometimes known as Luvox (brand name) - has been used mainly to treat obsessive-compulsive disorder (OCD), per the National Alliance on Mental Illness (NAMI). TreatEarly.org A meta-analysis of three previous trials on the drug’s effectiveness for COVID-19 treatment found “a high probability of being associated with reduced hospitalization in outpatients with COVID-19,” a study (April 2022) led by researchers from McGill University in Que